Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 402

1.
2.

Novel anti-angiogenic therapies for malignant gliomas.

Norden AD, Drappatz J, Wen PY.

Lancet Neurol. 2008 Dec;7(12):1152-60. doi: 10.1016/S1474-4422(08)70260-6. Review.

PMID:
19007739
3.

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS.

J Neurosurg. 2013 Dec;119(6):1415-23. doi: 10.3171/2013.7.JNS1323. Epub 2013 Oct 4.

4.

Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature.

Virrey JJ, Liu Z, Cho HY, Kardosh A, Golden EB, Louie SG, Gaffney KJ, Petasis NA, Schönthal AH, Chen TC, Hofman FM.

Mol Cancer Ther. 2010 Mar;9(3):631-41. doi: 10.1158/1535-7163.MCT-09-0652. Epub 2010 Mar 2.

5.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

6.

Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.

Kim CK, Joe YA, Lee SK, Kim EK, O E, Kim HK, Oh BJ, Hong SH, Hong YK.

Cancer Lett. 2010 Feb 28;288(2):251-60. doi: 10.1016/j.canlet.2009.07.008. Epub 2009 Aug 6.

PMID:
19664879
7.

Maturation of tumor vasculature by interferon-beta disrupts the vascular niche of glioma stem cells.

Williams RF, Sims TL, Tracey L, Myers AL, Ng CY, Poppleton H, Nathwani AC, Davidoff AM.

Anticancer Res. 2010 Sep;30(9):3301-8.

PMID:
20944101
8.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
10.

Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells.

Read TA, Farhadi M, Bjerkvig R, Olsen BR, Rokstad AM, Huszthy PC, Vajkoczy P.

Cancer Res. 2001 Sep 15;61(18):6830-7.

11.

Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice.

Barbieri F, Pattarozzi A, Gatti M, Aiello C, Quintero A, Lunardi G, Bajetto A, Ferrari A, Culler MD, Florio T.

Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1078-88. doi: 10.1152/ajpendo.00292.2009. Epub 2009 Aug 25.

12.

The radiosensitizing effect of CpG ODN107 on human glioma cells is tightly related to its antiangiogenic activity via suppression of HIF-1α/VEGF pathway.

Liu D, Cao G, Cen Y, Liu T, Peng W, Sun J, Li X, Zhou H.

Int Immunopharmacol. 2013 Oct;17(2):237-44. doi: 10.1016/j.intimp.2013.06.002. Epub 2013 Jun 19.

PMID:
23791618
13.

Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.

Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV.

Clin Cancer Res. 2005 Sep 15;11(18):6678-85.

14.

Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts.

Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F, Calvo A.

Lab Invest. 2012 Jul;92(7):952-66. doi: 10.1038/labinvest.2012.65. Epub 2012 Apr 30.

15.

Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.

Kraeber-Bodéré F, Bodet-Milin C, Niaudet C, Saï-Maurel C, Moreau A, Faivre-Chauvet A, Thomare P, Deleris G, Estieu-Gionnet K, Bikfalvi A, Barbet J, Paris F.

J Nucl Med. 2010 Apr;51(4):624-31. doi: 10.2967/jnumed.109.070714.

16.

The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.

Ruggeri BA, Robinson C, Angeles T, Wilkinson J 4th, Clapper ML.

Clin Cancer Res. 2002 Jan;8(1):267-74.

18.
19.

A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.

Luo Y, Jiang F, Cole TB, Hradil VP, Reuter D, Chakravartty A, Albert DH, Davidsen SK, Cox BF, McKeegan EM, Fox GB.

Cancer Chemother Pharmacol. 2012 Apr;69(4):911-21. doi: 10.1007/s00280-011-1740-7. Epub 2011 Nov 12.

PMID:
22080168
20.

MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.

Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, Gingles N, Peterson N, Fazenbaker C, Woods R, Jallal B, Ricketts SA, Lavallee T, Coats S, Chang Y.

Int J Oncol. 2012 May;40(5):1321-30. doi: 10.3892/ijo.2012.1366. Epub 2012 Feb 10.

PMID:
22327175

Supplemental Content

Support Center